CAS: 2143917-62-6; N-(6-(1-Methyl-1H-Pyrazol-4-yl)Isoquinolin-3-yl)-2-(4-Methylpiperazin-1-yl)Isonicotinamide

结构式图片

合成工艺路线路线简述

    📜N-(6-Bromo-3-Isoquinolyl)-2-(4-Methylpiperazin-1-yl)Pyridine-4-Carboxamide,1-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧杂戊硼烷-2-基)-1H-吡唑 在 [1,3-Bis(2,6-Diisopropylphenyl)Imidazol-2-Ylidene](3-Chloropyridyl)Palladium(Ll) Dichloride,Caesium Carbonate体系中,用 1,4-二氧六环,水作为反应溶剂,以52 %的收率获得2-(4-Methylpiperazin-1-yl)-N-[6-(1-Methylpyrazol-4-yl)-3-Isoquinolyl]Pyridine-4-Carboxamide
    参考文献:Comparative Efficacy And Selectivity Of Pharmacological Inhibitors Of Dyrk And Clk Protein Kinases
    标题:Comparative Efficacy And Selectivity Of Pharmacological Inhibitors Of Dyrk And Clk Protein Kinases
    摘要:
    Doi:10.1021/Acs.Jmedchem.2C02068

    海关参考信息

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1021/acs.jmedchem.1c00985
    摘要:Qin Z, Qin L, Feng X, Li Z, Bian J. Development of Cdc2-like Kinase 2 Inhibitors: Achievements and Future Directions. J Med Chem. 2021 Sep 23;64(18):13191–211. doi: 10.1021/acs.jmedchem.1c00985.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知